Fulcrum Therapeutics (FULC)

• Market cap: $252M
• 1 day: -2.30%
• 5 days: 7.09%
• 1 month: 20.62%
• 3 months: 31.09%
• 6 months: -25.83%
• Year to date: -35.09%
• 1 year: -35.09%
• 5 years: -73.18%
• 10 years: -65.33%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 89

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

254% more call options, than puts

Call options by funds: $25.5M | Put options by funds: $7.19M

20% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 35

6% more funds holding

Funds holding: 121 [Q2] → 128 (+7) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 35

18.25% less ownership

Funds ownership: 106.32% [Q2] → 88.07% (-18.25%) [Q3]

52% less capital invested

Capital invested by funds: $410M [Q2] → $197M (-$213M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 15% downside
• Avg. target: $4 15% downside
• High target: $4 15% downside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

RBC Capital Gregory Renza 39% 1-year accuracy 32 / 82 met price target	15% downside $4	Sector Perform Reiterated	14 Nov 2024
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 101 / 329 met price target	15% downside $4	Neutral Reiterated	14 Nov 2024